- Home
- ACRE vs HUMA Comparison
ACRE vs HUMA Comparison
Compare ACRE & HUMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ACRE | HUMA |
|---|---|---|
| Founded | 2011 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 254.1M | 236.0M |
| IPO Year | 2012 | N/A |
Fundamental Metrics
Financial Performance| Metric | ACRE | HUMA |
|---|---|---|
| Price | $4.70 | $1.01 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 8 |
| Target Price | $5.33 | ★ $10.13 |
| AVG Volume (30 Days) | 614.5K | ★ 4.9M |
| Earning Date | 02-11-2026 | 11-12-2025 |
| Dividend Yield | ★ 12.55% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $87,777,000.00 | $1,571,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $698.97 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 122.65 | N/A |
| 52 Week Low | $3.35 | $0.91 |
| 52 Week High | $6.21 | $5.48 |
Technical Indicators
Market Signals| Indicator | ACRE | HUMA |
|---|---|---|
| Relative Strength Index (RSI) | 31.16 | 34.63 |
| Support Level | $5.02 | $0.91 |
| Resistance Level | $5.55 | $1.17 |
| Average True Range (ATR) | 0.13 | 0.08 |
| MACD | -0.08 | -0.01 |
| Stochastic Oscillator | 3.45 | 19.47 |
Price Performance
Historical ComparisonAbout ACRE Ares Commercial Real Estate Corporation
Ares Commercial Real Estate Corp is a specialty finance company and a Real Estate Investment Trust providing commercial real estate loans and related investments. It operates in one segment namely originating and managing a diversified portfolio of CRE debt-related investments. The group recognizes its revenues through the interest income it receives from loans.
About HUMA Humacyte Inc.
Humacyte Inc is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Company's pipeline includes Vascular Trauma, PAD, Dailysis, Acellular Tissue Engineered Vessels, Organ Systems, Advanced Tissue Constructs.